Halozyme Therapeutics (HALO) Receives Daily News Impact Score of 0.05

About 186,275 shares traded. Acadian Asset Management LLC boosted its stake in shares of Five Prime Therapeutics by 1.6% in the third quarter. It has underperformed by 39.01% the S&P500. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Therefore 72% are positive. Devon Energy Corporation had 64 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has "Buy" rating by Argus Research given on Thursday, September 17. The stock has "Neutral" rating by Seaport Global on Wednesday, January 13. The firm has "Sell" rating given on Friday, August 21 by Zacks. The firm has "Accumulate" rating by Johnson Rice given on Thursday, May 19. They issued a "buy" rating and a $94.00 price objective on the stock. The firm has "Buy" rating by BMO Capital Markets given on Thursday, March 23. Its down 0.41, from 1.15 in 2016Q3.

Five Prime Therapeutics, Inc.is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. Cap Fund Mngmt reported 166,945 shares. Tiaa Cref Investment Mgmt Llc has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX).

Five Prime Therapeutics (NASDAQ:FPRX) traded down 0.42% during trading on Friday, reaching $33.00. Strs Ohio has 19,900 shares for 0% of their portfolio. Mackenzie reported 0.08% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX).

Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Thursday, February 23rd. (NASDAQ:HALO) will post ($0.26) earnings per share for the current quarter, Zacks Investment Research reports. Morgan Stanley owns 107,934 shares. Halozyme Therapeutics posted earnings of ($0.16) per share in the same quarter last year, which would indicate a negative year over year growth rate of 62.5%. Sector Pension Inv Board holds 40,604 shares or 0.01% of its portfolio. On average, equities analysts predict that Five Prime Therapeutics will post ($4.26) EPS for the current fiscal year. Axa holds 0% or 8,700 shares. For the next year, analysts anticipate that the firm will report earnings of ($0.83) per share, with EPS estimates ranging from ($0.97) to ($0.68).

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The company has market cap of $944.37 million. It now has negative earnings.

Analysts await Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings on May, 4. In the last quarter, insiders have sold 4,636 shares of company stock worth $218,760. Finally, Instinet began coverage on Five Prime Therapeutics in a report on Wednesday, March 1st. Finally, Credit Suisse Group restated a "buy" rating and set a $54.00 price target on shares of Five Prime Therapeutics in a report on Monday, November 7th. Therefore 86% are positive. Creative Planning raised its stake in Five Prime Therapeutics by 42.6% in the first quarter.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The rating was maintained by Credit Suisse with "Outperform" on Friday, March 11. The firm earned "Buy" rating on Friday, July 31 by Citigroup. The rating was initiated by Citigroup on Tuesday, October 25 with "Buy". Five Prime Therapeutics presently has an average rating of "Buy" and a consensus target price of $63.17. The rating was maintained by Oppenheimer on Monday, October 19 with "Outperform".

Since November 22, 2016, it had 0 insider purchases, and 4 insider sales for $664,773 activity.

In related news, insider Francis Willard Sarena sold 3,636 shares of the business's stock in a transaction on Wednesday, January 18th. BlackRock Fund Advisors now owns 1,080,243 shares of the company's stock worth $56,702,000 after buying an additional 71,528 shares during the period. 30,000 shares valued at $1.51M were sold by Williams Lewis T on Friday, December 23.

Investors sentiment decreased to 0.74 in 2016 Q4. Its down 0.02, from 1.17 in 2016Q3. 16 funds opened positions while 49 raised stakes. Basswood Capital Mngmt Limited Com invested in 0.85% or 674,091 shares. Sterneck Mgmt Limited Liability Corporation has 6,235 shares for 0.18% of their portfolio. 52,442 were accumulated by Advantus Inc. Oregon Pub Employees Retirement Fund invested in 0.12% or 126,821 shares. Metropolitan Life Ny holds 0.01% or 19,333 shares in its portfolio. Moreover, Baldwin Brothers Ma has 0.03% invested in Devon Energy Corp (NYSE:DVN) for 3,655 shares. Aperio Gp stated it has 170,834 shares or 0.06% of all its holdings. 10,000 BofI Holding, Inc. Thompson Rubinstein Investment Or holds 27,784 shares.

Devon Energy Corporation is an independent energy company. Adage Prns Grp Inc Ltd Limited Liability Company holds 0.26% or 1.90M shares in its portfolio. The Company's divisions include U.S., Canada and EnLink. Devon Energy Corp (NYSE:DVN) has declined 5.42% since September 9, 2016 and is downtrending.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Latest News